Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF

David A. Morrow,Eric Velazquez,Akshay Desai,Adam DeVore,Serge Lepage,Jeon-Gun Park,Kavita Sharma,Scott Solomon,Randall Starling,Jonathan Ward,Kristin Williamson,Shelley Zieroth,Adrian Hernandez,Robert Mentz,Eugene Braunwald

DOI: https://doi.org/10.1016/j.cardfail.2023.10.467

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Background PIONEER-HF and the recently completed PARAGLIDE-HF both evaluated the efficacy and safety of sacubitril/valsartan in patients hospitalized with heart failure (HF). This prespecified pooled analysis of PIONEER-HF (Ejection fraction [EF]≤40%) and PARAGLIDE-HF (EF>40%) examines outcomes with sacubitril/valsartan in patients stabilized after a worsening HF event across the spectrum of EF. Methods Both PIONEER-HF and PARAGLIDE-HF were multicenter, double-blind, randomized, controlled trials of sacubitril/valsartan vs. control therapy (enalapril or valsartan, respectively). All participants in PIONEER-HF and 69% in PARAGLIDE-HF were enrolled after hemodynamic stabilization during a hospitalization for HF. The remainder in PARAGLIDE-HF were enrolled within 30 days of an episode of worsening HF (including an emergency department or urgent HF visit requiring intravenous diuretic) and included in this analysis. The primary endpoint of both trials was time-averaged proportional change in NT-proBNP from baseline through Weeks 4 and 8. Clinical endpoints in both trials were adjudicated by the same independent clinical events committee and analyzed in all randomized patients through end of follow-up, adjusting for trial. Results The pooled analysis included 1347 patients (881 from PIONEER-HF and 466 from PARAGLIDE-HF). The median age was 66y. Overall, 36% were women, 31% were Black, 34% had de novo HF. The median EF was 30% (92% with EF ≤60%). Among those with requisite NTproBNP results (n= 1130), the time-averaged reduction in the NT-proBNP was 24% greater with sacubitril/valsartan vs. control (ratio of change, 0.76; 95% confidence interval [CI], 0.69-0.83; p<0.0001; Fig-Left). The composite of cardiovascular death or hospitalization for HF was reduced by 30% with sacubitril/valsartan vs. control (HR 0.70; 95% CI 0.54-0.91; p=0.0077). The clinical effect of sacubitril/valsartan was consistent across the spectrum of EF≤60% (Fig-Right, overall HR among those w/ EF≤60% 0.59; 95% CI 0.44-0.79) and when restricted to those hospitalized with HF (n=1133, HR 0.73; 95% CI 0.55-0.98). Sacubitril/valsartan increased symptomatic hypotension (RR, 1.35; 95%CI, 1.05-1.72) but trended toward a lower rate of worsening renal function (Risk Ratio [RR], 0.80; 95%CI, 0.64-1.003). Conclusion In a pooled analysis of randomized trials among patients hospitalized with HF, compared with control therapy, sacubitril/valsartan led to a greater reduction in plasma NT-proBNP level and improved clinical outcome across the spectrum of EF≤60%.

cardiac & cardiovascular systems